Signaling-Biased Dual GLP-1/GIP Agonist CT-388 Achieves Remarkable 8% Weight Loss in Just Four Weeks
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in metabolic disease management.